newest glp-1 medications for type 2 diabetes 2025 New Drug Approvals in 2025: What Clinicians Need to Know Treating Type 2 Diabetes in

one participant randomized to receive infusion with GLP-1 first was excluded due to significant age difference, in order to retain group homogeneity according to age

Oxidized low-density lipoprotein (ox-LDL) induces ferroptosis in macrophages and endothelial cells, releasing pro-inflammatory lipid mediators that recruit additional immune cells and perpetuate vascular inflammation

Liraglutide combined with resistance training and high-protein intake has demonstrated preservation of lean mass and strength, making it a suitable option in this setting [201]

some examples are presented below

14 Improved training performance may indirectly lead to better body composition as a secondary effect May decrease inflammation and improve recovery

If retatrutide achieves greater weight loss faster, patients may spend fewer total months on the medication to reach their goals, potentially offsetting a higher per-month cost